(0.00%) 5 469.41 points
(0.14%) 39 168 points
(0.25%) 17 761 points
(0.00%) $80.83
(-5.04%) $2.62
(-0.88%) $2 310.40
(-0.22%) $28.81
(3.22%) $1 018.20
(0.31%) $0.936
(0.72%) $10.68
(0.50%) $0.792
(-0.28%) $87.25
@ $38.99
Utstedt: 14 jun 2024 @ 17:03
Avkastning: -0.95%
Forrige signal: jun 14 - 15:30
Forrige signal:
Avkastning: -0.89 %
Live Chart Being Loaded With Signals
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers...
Stats | |
---|---|
Dagens volum | 343 276 |
Gjennomsnittsvolum | 1.26M |
Markedsverdi | 6.37B |
EPS | $-0.700 ( Q4 | 2024-05-08 ) |
Neste inntjeningsdato | ( $0 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-10.06 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0300 (0.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-20 | Horning Sandra | Buy | 4 800 | Common Stock |
2024-06-20 | Horning Sandra | Buy | 16 700 | Stock Option (Right to Buy) |
2024-06-20 | Patel Sushil | Buy | 4 800 | Common Stock |
2024-06-20 | Patel Sushil | Buy | 16 700 | Stock Option (Right to Buy) |
2024-06-20 | Borisy Alexis | Buy | 4 800 | Common Stock |
INSIDER POWER |
---|
75.77 |
Last 99 transactions |
Buy: 5 496 428 | Sell: 660 118 |
Volum Korrelasjon
Revolution Medicines Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
NKTR | 0.94 |
VCTR | 0.936 |
GDST | 0.934 |
BCSA | 0.928 |
FRLA | 0.925 |
GGAL | 0.923 |
PAYS | 0.923 |
IVCB | 0.923 |
SMTC | 0.922 |
BOCN | 0.92 |
10 Mest negative korrelasjoner | |
---|---|
LIQT | -0.929 |
ALLR | -0.928 |
SSYS | -0.927 |
SIRI | -0.927 |
WNEB | -0.922 |
INTC | -0.92 |
GLPG | -0.919 |
INTZ | -0.919 |
JACK | -0.917 |
MBIO | -0.916 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Revolution Medicines Inc Korrelasjon - Valuta/Råvare
Revolution Medicines Inc Økonomi
Annual | 2023 |
Omsetning: | $11.58M |
Bruttogevinst: | $2.27M (19.61 %) |
EPS: | $-3.86 |
FY | 2023 |
Omsetning: | $11.58M |
Bruttogevinst: | $2.27M (19.61 %) |
EPS: | $-3.86 |
FY | 2022 |
Omsetning: | $35.38M |
Bruttogevinst: | $25.72M (72.71 %) |
EPS: | $-3.08 |
FY | 2021 |
Omsetning: | $29.39M |
Bruttogevinst: | $29.39M (100.00 %) |
EPS: | $-2.57 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Revolution Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.